CVS Dropped Sanofi's Diabetes Drugs Lantus for Biosimilars
Shots:
- CVS dropped Sanofi's Lantus drug from the list of medicines & reimburses on behalf of health insurers. The company reported that the number of changes to its formulary & helped private-sector medical insurers to negotiate better prices from drugmakers and also draw up formularies
- Novartis and Actelion were also dealt blows by CVS’s new formulary. Additionally- the patent on Lantus has expired in 2015 in the US- and Sanofi hopes to revive declining diabetes sales with Toujeo which launched in Mar’15
- Sanofi shares decreased to 1.4% at 1250 GMT- its last week sales were decreased to 3.5 % at constant exchange rates to $1.8B
Ref: Biogen | Image: Stat News
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com